LTAS
SRPT icon

Linden Thomas Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Linden Thomas Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,609
Closed -$253K – 547
2026
Q1 		$253K Buy
11,609
+868
+8% +$16.8K 0.02% 487
2025
Q4 		$231K Sell
10,741
-879
-8% -$18.5K 0.02% 466
2025
Q3 		$224K Sell
11,620
-83
-0.7% -$1.48K 0.02% 462
2025
Q2 		$200K Sell
11,703
-106
-0.9% -$4.52K 0.02% 470
2025
Q1 		$754K Buy
11,809
+625
+6% +$65.8K 0.1% 321
2024
Q4 		$1.36M Sell
11,184
-375
-3% -$46K 0.17% 221
2024
Q3 		$1.44M Sell
11,559
-87
-0.7% -$12K 0.2% 202
2024
Q2 		$1.84M Buy
+11,646
New +$1.5M 0.28% 113

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Linden Thomas Advisory Services's SRPT Position: Q2 2026 in Review

Linden Thomas Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 11,609 shares — an estimated $253K sold.

Linden Thomas Advisory Services first reported a position in SRPT in Q2 2024 and held it in 8 quarters. The position peaked at $1.84M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Linden Thomas Advisory Services reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 11,609 Sarepta Therapeutics shares in Q2 2026, an estimated $253K.
  • Linden Thomas Advisory Services first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 8 quarters.
  • Linden Thomas Advisory Services's Sarepta Therapeutics position peaked at $1.84M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.